Keith Popovich
Pulmonary Disease · Butte, MTNPI 1467483412
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 58.6% of the total. Reporting peaked in 2019 at $1,085 and has fallen 56.7% since, to $470 in 2024.
Across 153 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$466
- Grifols USA, LLC$304
- Mylan Specialty L.p.$161
- Boehringer Ingelheim$120
- Sanofi$117
- plus $509 from 14 others
What the payments were for
- Food & beverage$4,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 65 | $2,374 |
| GSK | 23 | $466 |
| Grifols USA, LLC | 22 | $304 |
| Mylan Specialty L.p. | 8 | $161 |
| Boehringer Ingelheim | 6 | $120 |
| Sanofi | 5 | $117 |
| Actelion Pharmaceuticals US, Inc. | 3 | $93 |
| Sunovion Pharmaceuticals Inc. | 4 | $73 |
| Insmed, Inc. | 4 | $72 |
| Bayer | 2 | $50 |
| Harmony Biosciences LLC | 2 | $46 |
| Electromed, Inc. | 1 | $35 |
| Mallinckrodt Enterprises LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| United Therapeutics Corporation | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,050 in reported general payments places this provider in the 80th percentile of 43 pulmonary disease providers in Montana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $57,009 |
| NucalaMepolizumab | 11 | $40,577 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $26,278 |
| Spiriva RespimatTiotropium Bromide | 24 | $17,923 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,462 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $3,129 |
| Ventolin HfaAlbuterol Sulfate | 35 | $3,068 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 68 | $2,402 |
| Montelukast Sodium | 31 | $338 |
| Trazodone Hcl | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta | $466 | $108,048123 claims |
| AstraZenecaBreztri Aerosphere | $2,374 | $26,27837 claims |
| Boehringer IngelheimSpiriva Respimat | $120 | $17,92324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 pulmonary disease providers in Montana.
Other pulmonary disease in Butte
- Gregory LemenseBozeman$39K
- Megan SiskGreat Falls$20K
- John MazurGreat Falls$18K
- Bethany WeilerKalispell$14K
- Gabor VarjuGreat Falls$10K
- Andrew GoldbergBozeman$6K
- Dillon NolandKalispell$6K
- Ryan NahapetianMissoula$5K
- Fernando CaceresBillings$2K
- Vineeth KumarBillings$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.